TNO155: Clinical Trials

3 trials of TNO155, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting, 1 unknown. 3 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 13Active not recruiting 2, Unknown 1
Phase 23Active not recruiting 2, Unknown 1

Follow TNO155: new trials by email Literature Review of TNO155 trials Research Report on TNO155

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
Opnurasib, TNO155, trametinib - Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation
Phase 1 / Phase 2Active not recruitingNovartis Pharmaceuticals252026-06-082026-10-23
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
JDQ443, TNO155, tislelizumab - KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung
Phase 1 / Phase 2Active not recruitingNovartis Pharmaceuticals3442021-02-242026-10-19
Lorlatinib Combinations in Lung Cancer
Lorlatinib, Crizotinib, Binimetinib - Lung Cancer, Anaplastic Lymphoma Kinase Gene Translocation
Phase 1 / Phase 2UnknownMassachusetts General Hospital962020-05-012021-03-10

Conditions studied

Carcinoma, Non-Small-Cell Lung (2)  ·  Colorectal Neoplasms (2)  ·  Lung Neoplasms (2)  ·  Neoplasm Metastasis (1)  ·  Recurrence (1)

Sponsors

Novartis Pharmaceuticals (2)  ·  Massachusetts General Hospital (1)

Countries

Belgium (2)  ·  Canada (2)  ·  China (2)  ·  Denmark (2)  ·  France (2)  ·  Italy (2)  ·  Japan (2)  ·  South Korea (2)  ·  Spain (2)  ·  United States (2)  ·  Australia (1)  ·  Germany (1)  ·  Hong Kong (1)  ·  Malaysia (1)  ·  Netherlands (1)

Top investigators

Ibiayi Dagogo-Jack, MD (1)

Results publications

PMID 36399068

NIH funding

2025 (1)